Top View
- ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-Up† D
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Hazardous Drug Acknowledgement Statement
- Medical Benefit Injectable Drugs | Kaiser Permanente Washington
- 2019 Table of Drugs
- NIOSH Hazardous Drugs Table 1 Antineoplastic Drugs
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Effectiveness of an Algorithm-Based Approach to Filgrastim-Based
- Drug and Nutrition in Cancer Patient
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
- Clinical Practice Guidelines for the Prevention and Treatment of EGFR Inhibitor-Associated Dermatologic Toxicities
- Pharmacist Involvement in the Management of Adverse Effects
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Development of the Rat Model of Lapatinib-Induced Diarrhoea
- National Direct Drug List
- SUMMARY of DRUG LIMITATIONS Medications Listed in This Document May Or May Not Require a Prior Authorization
- New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Effects of Palifermin on Antitumor Activity of Chemotherapeutic and Biological Agents in Human Head and Neck and Colorectal Carcinoma Xenograft Models
- Palifermin for the Reduction of Acute GVHD: a Randomized, Double-Blind, Placebo-Controlled Trial
- Acute Mucositis and Gastrointestinal Toxicity Caused by Radiotherapy Or Systemic Anti-Cancer Treatment 2019
- Cetuximab) on Mnsod-Plasmid Liposome Transgene Radiosensitization of a Murine Squamous Cell Carcinoma Cell Line
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Attachment 1
- Standard Oncology Criteria Policy Number: Pending
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Adverse Mucocutaneous Reactions to Chemotherapeutic Agents - Part I Reações Tegumentares Adversas Relacionadas Aos Agentes Antineoplásicos – Parte I
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Fast Track Approvals (Through 3-31-2007)
- Mutation Based Treatment Recommendations from Next Generation Sequencing Data: a Comparison of Web Tools
- KEPIVANCE® (Palifermin) for Injection, for Intravenous Use ------CONTRAINDICATIONS------ Initial U.S
- Oncology Medications and Supportive Agents Require Review by New
- Biologics and Biosimilars: Background and Key Issues
- Kepivance® (Palifermin)
- European Patent Office of Opposition to That Patent, in Accordance with the Implementing Regulations
- Do Not Tube List
- ANTICANCER THERAPY-INDUCED MUCOSITIS and DIARRHOEA: Prevalence and Management Strategies Florian SCOTTE, Mdphd Suresnes, France DISCLOSURES
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Kepivance®) Place of Service Ambulatory Center Only
- Translating Discoveries Into Cures for Children with Cancer
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- P & T: January 10, 2019
- Boards Fodder DIRECTIONS RESIDENCY In
- HOPA News Volume 9, Issue 1
- PHYSICIAN ADMINISTERED DRUG PROGRAM (PADP) FEE SCHEDULE EFFECTIVE JANUARY 1, 2021 the Inclusion of a Rate on This Table Does Not Guarantee That a Service Is Covered